Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 63 Lymphoma, Large B-Cell, Diffuse 60 Lymphoma 57 Lymphoma, Non-Hodgkin 54 Lymphoma, Follicular 43 Lymphoma, Mantle-Cell 31 Lymphoma, B-Cell, Marginal Zone 26 Lymphoma, B-Cell 26 Precursor Cell Lymphoblastic Leukemia-Lymphoma 20 Leukemia 19 Burkitt Lymphoma 19 Waldenstrom Macroglobulinemia 16 Recurrence 16 Hodgkin Disease 13 Multiple Myeloma 9 Lymphoma, Large-Cell, Immunoblastic 9 Hematologic Neoplasms 8 Leukemia, Myeloid, Acute 7 Neoplasms, Plasma Cell 6 Neoplasms 6 Myelodysplastic Syndromes 6 Leukemia, Prolymphocytic 6 Lymphoma, T-Cell 5 Intraocular Lymphoma 5 Leukemia, Hairy Cell 4 Neoplasm Metastasis 3 Myeloproliferative Disorders 3 Lymphoma, T-Cell, Peripheral 3 Leukemia, Myeloid, Chronic-Phase 3 Leukemia, B-Cell 3

Interventions

selinexor 1 Rituximab 1 Ifosfamide 1 Etoposide 1 Dexamethasone 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Aggression × Rituximab × Clear all

NCT02471911 2022-04-12

KPT-330+RICE

Weill Medical College of Cornell University

Phase 1 Completed

Aggression, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡